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Abstract 
Objective: This study examined the individual and combined impact of N-terminal pro-B-
type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), 
interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) on the prediction of 
heart failure incidence or progression in patients with type 2 diabetes. 
Research Design and Methods: A nested case-cohort study was conducted in 3,098 
participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. 
Results: A higher value of each biomarker was significantly associated with a higher risk of 
heart failure incidence or progression, after adjustment for major risk factors. The hazard 
ratios per 1-SD increase were 3.06 (95% CI 2.37-3.96) for NT-proBNP, 1.50 (1.27-1.77) for 
hs-cTnT, 1.48 (1.27-1.72) for IL-6, and 1.32 (1.12-1.55) for hs-CRP. Addition of NT-
proBNP to the model including conventional risk factors meaningfully improved 5-year risk 
predictive performance (c-statistic 0.8162 to 0.8800; continuous net reclassification 
improvement [NRI] 73.1%; categorical NRI [<5%, 5-10%, >10% 5-year risk] 24.2%). In 
contrast, addition of hs-cTnT, IL-6 or hs-CRP did not improve the prediction metrics 
consistently either in combination or when added to NT-proBNP. 
Conclusions: Only NT-proBNP, strongly and consistently improved prediction of heart 
failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and 
biomarkers. 
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Abbreviations: 
ACR: albumin-to-creatinine ratio 
ADVANCE: Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation 
ECG: electrocardiogram 
eGFR: estimated glomerular filtration rate 
HR: hazard ratio 
HbA1c: hemoglobin A1c 
hs-CRP: high-sensitivity C-reactive protein 
hs-cTnT: high-sensitivity cardiac troponin T 
IDI: integrated discrimination index 
IL-6: interleukin-6 
NRI: net reclassification improvement 
NT-proBNP: N-terminal pro-B-type natriuretic peptide 
SD: standard deviation
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 The number of people with heart failure has been increasing, most likely the result of 
ageing and the increasing prevalence of hypertension, diabetes, obesity and atherosclerotic 
disease (1). Heart failure increases mortality, hospitalization and decreases health-related 
quality of life and functional status, and also results in increasing medical costs (1). Therefore, 
prevention and management of heart failure is an important global public health problem. 
 
 Diabetes is one of the major risk factors for heart failure, being associated with over 
50% increase in risk (2), and has strong adverse effects on the prognosis of heart failure (3). 
Heart failure has also been noted to be the second most common first presentation of CVD in 
patients with type 2 diabetes and more common than myocardial infarction (2). Yet 
insufficient emphasis has been placed on the prevention and treatment of heart failure in the 
clinical management of diabetes (4). 
 
 Recently, several circulating biomarkers, such as C-reactive protein (CRP) (5), 
interleukin-6 (IL-6) (6), N-terminal pro-B-type natriuretic peptide (NT-proBNP) (7,8), and 
high-sensitivity cardiac troponin T (hs-cTnT) (9), have been shown to be associated with the 
incidence of CVD. It has also been suggested that these biomarkers may be useful in 
predicting the risk of heart failure. However, few studies have examined the association 
between these biomarkers and the risk of heart failure in patients with diabetes, and it is 
uncertain how well these biomarkers can classify the risk of heart failure in such patients. 
Given limited medical resources and costs, efficient identification of high risk patients for 
subsequent precise evaluation and intervention is crucial. 
 
 The objective of the present study was thus to examine the association of circulating 
cardiac stress (NT-proBNP for myocardial stretch and volume overload and hs-cTnT for 
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myocardial damage) and inflammatory (high-sensitivity C-reactive protein [hs-CRP] and IL-
6) markers with the risk of heart failure and their additional risk predictive ability beyond that 
from traditional clinical risk factors in patients with type 2 diabetes. 
 
Research Design and Methods 
Study sample 
 We conducted a nested case-cohort study to examine the association between cardiac 
stress biomarkers and inflammatory markers and heart failure in patients with type 2 diabetes 
who participated in Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE) study (ClinicalTrials.gov number 
NCT00145925). The design and results of ADVANCE have been published in detail 
previously (10-12). Briefly, 11,140 patients with type 2 diabetes at high risk of cardiovascular 
events were enrolled from 215 centers in 20 countries, and randomly assigned to either a 
gliclazide (modified release)-based intensive glucose control strategy (target HbA1c ≤6.5 %) 
or standard glucose control strategy based on local guidelines and to either a fixed-dose 
combination of perindopril (4 mg) and indapamide (1.25 mg) or matching placebo, after a 6-
week active run-in period. Approval for the study was obtained from each center’s 
institutional review board. All participants provided written informed consent. 
 Baseline data included demographic and clinical information. Weight, height, blood 
pressure, hemoglobin A1c (HbA1c), fasting lipid levels, urinary albumin-to-creatinine ratio 
(ACR) and serum creatinine were measured. The estimated glomerular filtration rate (eGFR) 
was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (13). 
Twelve-lead electrocardiograms (ECGs) were obtained at baseline for the presence of atrial 
fibrillation, left ventricular hypertrophy, and pathological Q-waves. Atrial fibrillation was 
considered present when it was identified by the investigator on the baseline ECG or when 
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atrial fibrillation confirmed by ECG had been previously diagnosed. 
 Plasma samples were obtained from all study participants at baseline and stored at -80℃ 
for a median of 7.8 years. Samples were available from all countries involved in ADVANCE, 
except China and India, giving a total population of 7,376. For the nested case-cohort study 
(14), a random subcohort of 3,500 participants was selected from this base population, plus 
131 additional participants who had experienced a heart failure event during 5-year follow-up 
(Supplemental Figure 1). 
 High-sensitivity IL-6 levels was assayed by ELISA (R&D Systems, Oxford, U.K.) and 
high-sensitivity CRP by immunonephelometry (ProSpec; Dade Behring, Milton Keynes, 
U.K.) (15). NT-proBNP and hs-cTnT were assayed by electrochemiluminescence 
immunoassays performed on a Roche Elecsys 2010 automated platform (Roche Diagnostics, 
Burgess Hill, U.K.) (16,17). A detailed description of the measurement of stored samples has 
been published previously (15-17). 
 
Study Outcome 
 In this project, the study outcome was incidence or progression of heart failure (death 
due to heart failure, hospitalization due to heart failure, or worsening New York Heart 
Association class). 
 
Statistical analysis 
 Categorical data are presented as number (percentage) and continuous data as mean 
(SD), where approximately symmetrically distributed, or median (interquartile range), where 
skewed. Differences in the mean values or proportions of the baseline characteristics of the 
patients according to outcome status were tested by chi-square test, unpaired t-test or 
Wilcoxon test, as appropriate. Hazard ratios (HRs) for incidence or progression of heart 
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failure were calculated by weighted Cox regression models for case-cohort analyses using 
groups defined by the fifths and for a one standard deviation (SD) increase in each of IL-6, 
hs-CRP, hs-cTnT, and NT-proBNP, after log transformation. Three models, with different 
potential confounding variables, were fitted for each biomarker-heart failure combination: 
model 1 with age, sex, randomized blood pressure-lowering intervention, and randomized 
glucose control intervention; model 2 with, additionally, duration of diabetes mellitus, current 
smoking, history of myocardial infarction, history of hospitalization for heart failure, BMI, 
systolic blood pressure, heart rate, current or previous atrial fibrillation, pathological Q-wave 
on ECG, left ventricular hypertrophy on ECG, aspirin or other antiplatelet agent use, β-
blocker use, calcium-channel blocker use, diuretics use, angiotensin-converting enzyme 
inhibitors or angiotensin II receptor blockers use, total cholesterol, HDL cholesterol, 
triglyceride, statin or other lipid-lowering agent, HbA1c, thiazolidinedione use, insulin use, 
urinary ACR and eGFR; and model 3 with, additionally to model 2, the other three 
biomarkers. Pre-defined subgroup analyses, using model 2, were performed by baseline 
history of heart failure, history of myocardial infarction, sex, age (split at its median), and 
duration of diabetes (also split at its median). 
 Prediction metrics for heart failure were calculated in the random subcohort. 
Discrimination was evaluated by c statistics for 5-year risk, accounting for censoring (18), 
and compared between model 2 and model 2 plus each biomarker individually and in 
combination. In addition, the ability of each biomarker to better classify the 5-year risk for 
incidence or progression of heart failure, compared to model 2, was evaluated by the 
integrated discrimination index (IDI) and the net reclassification improvement (NRI), using 
methods suitable for survival data (14). NRI was calculated by a continuous model for 
changes in risk classification and a categorical model based on <5%, 5-10%, and >10% 5-
year risk. 
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 In addition, sensitivity analyses were conducted after excluding 1) patients with a 
history of hospitalization for heart failure (n = 136) and 2) patients with NT-proBNP levels 
>400 pg/mL (n = 391). All analyses were performed using SAS Enterprise Guide 7.11 (SAS 
Institute Inc., Cary, NC) or Stata software (release 13; StataCorp, College Station, TX, USA). 
A two-sided P <0.05 was considered to be statistically significant in all analyses. 
 
Results 
 A total of 3,631 patients comprised the entire case-cohort study. After a number of 
exclusions, shown in Supplemental Figure 1 (283 patients with insufficient stored plasma for 
measurement of biomarkers and 250 with missing values for covariates), the remaining 3,098 
patients were included in the present analysis. During a median follow-up of 5.0 years, 237 
experienced a heart failure event. Table 1 shows the baseline characteristics of study 
participants. 40% of the cohort was female, and the mean age was 67 years. IL-6, hs-CRP, 
hs-cTnT and NT-proBNP levels were significantly higher in patients who experienced a heart 
failure event. 
 
 The HRs and 95% CIs for heart failure according to fifths of each biomarker are 
depicted in Figure 1. The risk of heart failure increased significantly with increasing levels of 
all the biomarkers after adjustment for age, sex, randomized blood pressure-lowering and 
glucose control interventions, and clinical risk factors (all P for trend <0.01 in model 2). 
Multivariable-adjusted HRs (95% CIs) for the highest fifths compared with the lowest fifths 
were 2.62 (1.48-4.63) for IL-6, 2.22 (1.33-3.72) for hs-CRP, 2.70 (1.68-4.34) for hs-cTnT, 
and 12.53 (5.41-29.02) for NT-proBNP. Figure 2 shows the HRs and 95% CIs for heart 
failure according to a 1 SD increment in each biomarker. Higher values of all four biomarkers 
were significantly associated with higher risk of heart failure after adjusting for clinical risk 
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factors (Model 2, all P <0.001). After further adjustment for the other biomarkers (Model 3), 
associations were attenuated and became non-significant for hs-CRP and hs-cTnT. In all 
adjustment sets, NT-proBNP showed the strongest association with heart failure (HR 2.77 
[95% CI 2.12-3.63] in model 3). Broadly similar findings were observed in the sensitivity 
analyses after excluding patients with past history of hospitalization for heart failure 
(Supplemental Figure 2) or those with NT-proBNP levels >400 pg/mL (Supplemental Figure 
3), though the associations were slightly attenuated when patients with NT-proBNP levels 
>400 pg/mL were excluded. There was no evidence of effect modification in the association 
between heart failure and NT-proBNP by sex, age, duration of diabetes, or history of 
hospitalization for heart failure (model 2, Supplemental Figure 4). Although significant 
heterogeneity (P = 0.004) was observed in the association in those with (HR=2.28 [95% CI 
1.08-4.81]) and without (HR=3.52 [95% CI 2.66-4.66]) a history of myocardial infarction, the 
direction of the association was the same in both groups. 
 
 Addition of NT-proBNP to a model including conventional risk factors (model 2) 
greatly improved discrimination and classification of the 5-year risk of heart failure (c-
statistic: 0.8162 to 0.8800, P <0.001; IDI: 0.107, P <0.001; continuous NRI: 0.731, P <0.001, 
categorical NRI: 0.242, P <0.001) (Table 3). On the other hand, when any of IL-6, hs-CRP, or 
hs-cTnT was added to model 2, the improvements were not uniformly significant. NT-
proBNP alone showed comparable predictive ability compared with a comprehensive set of 
conventional risk factors (c-statistic: 0.8239 vs. 0.8162, P = 0.74). 
 Addition of NT-proBNP to model 2 plus IL-6, hs-CRP, and hs-cTnT significantly 
improved the c-statistic (0.8384 to 0.8816, P <0.001) and classification of outcomes (IDI: 
0.081, P <0.001; continuous NRI: 0.664, P <0.001; categorical NRI: 0.191, P <0.001). On 
the other hand, addition of a combination of IL-6, hs-CRP, and hs-cTnT to model 2 plus NT-
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proBNP improved classification (IDI: 0.029, P = 0.002; continuous NRI: 0.304, P = 0.002; 
categorical NRI: 0.010, P = 0.56), but did not improve discrimination (c-statistic: 0.8800 to 
0.8816, P = 0.65). Almost identical results were obtained when patients with past history of 
hospitalization for heart failure or those with NT-proBNP levels >400 pg/mL were excluded 
(Supplemental Tables 1 and 2). 
 
Conclusions 
 To the best of our knowledge, this is the first study to examine the improvement in the 
risk predictive ability for future heart failure by adding biomarkers to conventional risk 
factors in patients with type 2 diabetes, using a comprehensive set of prediction metrics. 
Higher values of IL-6, hs-CRP, hs-cTnT, and NT-proBNP were significantly associated with 
a higher risk of incidence or progression of heart failure in patients with type 2 diabetes. 
These associations persisted after adjusting for a comprehensive set of conventional CVD 
risk factors. In addition, incorporation of NT-proBNP into a prediction model greatly 
improved discrimination and classification of the 5-year risk of heart failure beyond 
conventional use of risk factors. In contrast, none of IL-6, hs-CRP, and hs-cTnT provided 
clinically useful incremental information. These data were broadly similar in those with no 
previous history of heart failure hospitalization and when those with NT-proBNP levels >400 
pg/mL were excluded.  
 A number of studies have reported that the usefulness of newly identified biomarkers 
such as NT-proBNP, hs-cTnT, hs-CRP, and IL-6 to predict incident heart failure (19,20). 
However, few studies have investigated prognostic ability for heart failure in patients with 
diabetes. A sub-analysis of the Steno-2 study found that NT-proBNP levels above the median 
of the study population were associated with an increased risk of a composite of 
cardiovascular mortality and hospitalization for congestive heart failure in 160 
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microalbuminuric patients with type 2 diabetes (21). Another observational study from the 
SAVOR-TIMI 53 randomized trial, among 12,301 patients with type 2 diabetes, also showed 
a stepwise increased risk of hospitalization for heart failure with increasing levels of NT-
proBNP, with no evidence of heterogeneity among those taking saxagliptin treatment or 
placebo (22). The addition of NT-proBNP to the model with clinical variables increased the 
c-statistic from 0.81 to 0.85 (22). The present study adds to these prior studies by providing 
evidence that NT-proBNP considerably improved risk prediction for heart failure beyond that 
derived from a wide range of clinical risk factors, using a comprehensive set of 
discrimination and reclassification metrics. Addition of NT-proBNP to the model with 
clinical risk factors increased the c-statistic and improved IDI, continuous NRI, and 
categorical NRI. These findings suggest that assessment of NT-proBNP will help to identify 
those at high risk who should go on to further investigation, such as undergoing an 
echocardiogram, and intervention. 
 There is only one prior study examining the association between CRP and heart failure 
in patients with diabetes, and none examining associations for IL-6 and hs-cTnT. In a 
subgroup analysis from the Strong Heart Study, elevated CRP levels were associated with 
incident heart failure in American Indians with diabetes (23). Our findings are consistent and 
extend to patients with diabetes from a range of countries across Australasia, Europe and 
North America. In addition, our study adds new information on the relationship between the 
risk of heart failure and IL-6 and hs-cTnT levels, with findings showing an elevated risk of 
heart failure with increasing levels in these markers but no improvements in prediction 
metrics when added to a model with traditional clinical risk factors.  
 Only addition of NT-proBNP to the model with clinical risk factors and the other three 
biomarkers strongly improved prognostic ability. On the other hand, addition of a 
combination of IL-6, hs-CRP and hs-cTnT to the model with clinical risk factors and NT-
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proBNP had no such benefit. This suggests that NT-proBNP adds to predictive capacity for 
the incidence of heart failure and could be added to routine assessment of the risk. 
 Recently, the EMPAREG-REG OUTCOME trial reported that patients with type 2 
diabetes who received empagliflozin, an inhibitor of sodium-glucose cotransporter 2, had a 
significantly lower risk of hospitalization for heart failure than those in the placebo group 
(24). This association may be partly driven by osmotic diuresis and changes in plasma 
volume and sodium excretion with modulation of the cardio-renal axis mediated by 
empagliflozin (25,26). NT-proBNP is a cardiac hormone secreted by cardiac myocytes in 
response to ventricular wall stresses secondary to volume and pressure overload (27). Thus 
risk prediction for heart failure using NT-proBNP could more accurately identify those 
patients who may benefit most from this kind of drug. Future interventional studies are 
required to ascertain the utility of this possible strategy. 
 The strengths of the present study include its large sample size, international 
recruitment in a well-characterized trial population, which was closely monitored and treated 
uniformly, completeness of follow-up, and adjustment for a variety of risk factors. In addition, 
this is the first study to examine the additional predictive ability of biomarkers beyond 
conventional risk factors, using a comprehensive range of prediction statistics, in patients 
with type 2 diabetes. Some limitations of our study should be discussed. First, a single 
measurement of levels of biomarkers may not accurately represent the true status of the 
participants. However, this would bias our results toward the null hypothesis of no 
association. Therefore, the true association may be stronger than that observed in the present 
study. Second, the participants in this study were those eligible for the clinical trial. Therefore, 
applicability of the present findings to the general populations of patients with diabetes may 
not be justified, although the characteristics of the ADVANCE cohort of baseline were 
similar to those reported by a number of community based epidemiological studies (28). 
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Finally, there may be other possible confounders besides those used in the current study, 
leading to bias by residual confounding. 
 
 In conclusion, we found that IL-6, hs-CRP, hs-cTnT, and NT-proBNP were 
independent predictors of incidence of heart failure in patients with type 2 diabetes. However, 
only the addition of NT-proBNP materially improved the predictive performance for heart 
failure beyond that from conventional clinical risk factors. Further studies are needed to 
validate our findings. 
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Table 1. Baseline characteristics according to outcome status 
 Heart failure event Overall 
Variables 
Yes 
n=237 
No 
n=2,861 
 
n=3,098 
    Female (%) 83 (35) 1,162 (41) 1,245 (40) 
    Age (years) 70 (7)* 66 (7) 67 (7) 
    Duration of diabetes mellitus (years) 10.0 (7.6)* 7.5 (6.2) 7.7 (6.3) 
    Current smoking (%) 30 (13) 426 (15) 456 (15) 
    History of myocardial infarction (%) 61 (26)* 98 (3) 159 (5) 
    History of hospitalization for heart failure 
(%) 
38 (16)* 98 (3) 136 (4) 
    BMI (kg/m2) 30.7 (5.6) 30.0 (5.2) 30.0 (5.2) 
    SBP (mmHg) 149 (23) 147 (21) 147 (21) 
    DBP (mmHg) 80 (12)* 82 (11) 82 (11) 
    Heart rate (bpm) 74 (13) 73 (12) 73 (12) 
    Current or previous atrial fibrillation (%) 49 (21)* 275 (10) 324 (10) 
    Pathological Q-wave on ECG (%) 51 (22)* 307 (11) 358 (12) 
     LVH on ECG (%) 37 (16)* 222 (8) 259 (8) 
    Aspirin or other antiplatelet agent (%) 143 (60)* 1,378 (48) 1,521 (49) 
    β-blocker (%) 71 (30) 856 (30) 927 (30) 
    Calcium-channel blocker (%) 106 (45)* 815 (28) 921 (30) 
    Diuretics¶ (%) 119 (50)* 823 (29) 942 (30) 
    ACE inhibitors¶ or ARB (%) 175 (74)* 1,628 (57) 1,803 (58) 
    Total cholesterol (mmol/l) 5.03 (1.13) 5.16 (1.17) 5.15 (1.17) 
    HDL cholesterol (mmol/l) 1.17 (0.28)* 1.23 (0.33) 1.23 (0.33) 
    Triglyceride (mmol/l) 1.60 (1.22, 2.30) 1.70 (1.20, 2.34) 1.70 (1.20, 2.33) 
    Statin or other cholesterol-lowering agent 
(%) 
101 (43) 1,265 (44) 1,366 (44) 
    Hemoglobin A1c (%) 7.8 (1.5)* 7.4 (1.4) 7.4 (1.4) 
    Hemoglobin A1c (mmol/mol) 61.3 (16.0)* 56.9 (15.1) 57.2 (15.2) 
    Thiazolidinedione (%) 7 (3) 126 (4) 133 (4) 
    Other oral antidiabetic agents (%) 219 (92) 2,562 (90) 2,781 (90) 
    Insulin (%) 4 (2) 37 (1) 41 (1.3) 
    Urinary ACR (µg/mg) 30.9 (10.4, 91.1)* 12.9 (6.2, 32.7) 13.5 (6.2, 36.2) 
    eGFR (ml/min/1.73m2) 63 (18)* 73 (16) 72 (17) 
    IL-6 (pg/mL) 3.05 (2.13, 4.49)* 2.19 (1.57, 3.21) 2.26 (1.61, 3.33) 
    
hs-CRP (mg/L) 2.35 (1.19, 5.89)* 1.75 (0.84, 3.91) 1.80 (0.86, 4.03) 
    hs-cTnT (ng/L) 12.0 (6.0, 20.0)* 5.0 (1.5, 10.0) 5.0 (1.5, 10.0) 
    
NT-proBNP (pg/mL) 
353.0 
(131.0, 819.0)* 
75.0 
(31.0, 172.0) 
84.0 
(33.0, 203.0) 
Values are mean (standard deviation) for continuous variables (except for triglycerides, urinary albumin-
creatinine ratio, IL-6, hs-CRP, hs-cTnT, and NT-proBNP), median (interquartile range) for triglycerides, urinary 
albumin-creatinine ratio, IL-6, hs-CRP, hs-cTnT, and NT-proBNP, and number (%) for categorical variables. 
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Abbreviations: ACE, Angiotensin-converting enzyme; ACR, albumin-creatinine ratio; ARB, angiotensin II 
receptor blocker; DBP, diastolic blood pressure; ECG, electrocardiogram; eGFR, estimated glomerular filtration 
rate; hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IL-6, interleukin-
6; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, systolic 
blood pressure. 
* P <0.05 vs patients without heart failure event. 
¶ Randomized BP-lowering treatment with perindopril-indapamide was not included. 
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Table 2. Discrimination and reclassification statistics (95% CIs) for 5-year risk of heart failure after addition of biomarkers to a model containing clinical risk factors 
 
   NRI 
C-statistic IDI Relative IDI (%) Continuous Categorical† 
Base model* 0.8162 (0.7785, 0.8540)     
Base model plus IL-6 0.8264 (0.7904, 0.8624) 0.029 (0.008, 0.050) 8.73 (2.38, 15.98) 0.393 (0.210, 0.569) 0.030 (-0.053, 0.108) 
 P = 0.052 P = 0.006  P <0.001 P = 0.45 
Base model plus hs-CRP 0.8261 (0.7900, 0.8621) 0.018 (0.003, 0.034) 5.50 (0.91, 10.45) 0.215 (0.036, 0.387) 0.092 (0.024, 0.160) 
 P = 0.11 P = 0.02  P = 0.03 P = 0.008 
Base model plus hs-cTnT 0.8253 (0.7888, 0.8618) 0.020 (0.004, 0.038) 6.08 (1.19, 11.70) 0.403 (0.223, 0.583) 0.065 (-0.008, 0.140) 
 P = 0.22 P = 0.01  P <0.001 P = 0.07 
Base model plus NT-proBNP 0.8800 (0.8529, 0.9072) 0.107 (0.064, 0.154) 32.2 (18.2, 49.3) 0.731 (0.564, 0.892) 0.242 (0.145, 0.342) 
 P <0.001 P <0.001  P <0.001 P <0.001 
      
Base model plus IL-6, hs-CRP, and 
hs-cTnT 
0.8384 (0.8040, 0.8729)     
Addition of NT-proBNP 
to base model plus IL-6, 
hs-CRP, and hs-cTnT 
0.8816 （0.8546, 0.9085） 0.081 (0.043, 0.123) 20.8 (10.4, 32.6) 0.664 (0.492, 0.828) 0.191 (0.105, 0.287) 
P <0.001 P <0.001  P <0.001 P <0.001 
      
Base model plus NT-proBNP 0.8800 (0.8529, 0.9072)     
Addition of IL-6, hs-CRP, and 
hs-cTnT 
to base model plus NT-proBNP  
0.8816 (0.8546, 0.9085) 0.029 (0.010, 0.049) 6.57 (2.21, 11.2) 0.304 (0.117, 0.497) 0.010 (-0.040, 0.059) 
P = 0.65 P = 0.002  P = 0.002 P = 0.56 
Results were derived from the random subcohort (n = 2,989). 
Biomarkers were log transformed. 
* Base model included age, sex, randomised blood pressure-lowering intervention, randomised glucose control intervention, duration of diabetes mellitus, current 
smoking, history of myocardial infarction, history of hospitalization for heart failure, BMI, systolic blood pressure, heart rate, current or previous atrial fibrillation, 
pathological Q-wave on ECG, left ventricular hypertrophy on ECG, aspirin or other antiplatelet agent use, β-blocker use, calcium-channel blocker use, diuretics use, 
angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers use, total cholesterol, HDL cholesterol, triglyceride, statin or other lipid-lowering agent, 
hemoglobin A1c, thiazolidinedione use, insulin use, urinary albumin-creatinine ratio, and estimated glomerular filtration rate. 
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† Using cutoff points of 5% and 10% 5-year risk. 
Abbreviations: IDI, integrated discrimination improvement; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; 
IL-6, interleukin-6; NRI, net reclassification improvement; NT-proBNP, N-terminal pro-B-type natriuretic peptide. 
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Figure legends 
Figure 1: Adjusted hazard ratios and 95% CIs for heart failure according to fifths 
of the biomarker. 
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity 
cardiac troponin T; IL-6, interleukin-6; NT-proBNP, N-terminal pro-B-type natriuretic 
peptide. 
Each biomarker was categorized into 5 groups according to the fifths. The ranges of IL-
6 were 0.19-1.48, 1.49-1.95, 1.96-2.58, 2.59-3.68, and 3.69-16.13 pg/mL. The ranges of 
hs-CRP were 0.08-0.73, 0.74-1.33, 1.34-2.45, 2.46-4.75, and 4.78-130.00 mg/L. The 
ranges of hs-cTnT were 1.5, 3.0, 4.0-6.0, 7.0-12.0, and 13.0-751.0 ng/L. The ranges of 
NT-proBNP were 2.5-24.0, 25.0-59.0, 60.0-116.0, 117.0-255.0, and 256.0-35000.0 
pg/mL. 
Hazard ratios were adjusted for age, sex, randomised blood pressure-lowering 
intervention, randomised glucose control intervention, duration of diabetes mellitus, 
current smoking, history of myocardial infarction, history of hospitalization for heart 
failure, BMI, systolic blood pressure, heart rate, current or previous atrial fibrillation, 
pathological Q-wave on ECG, left ventricular hypertrophy on ECG, aspirin or other 
antiplatelet agent use, β-blocker use, calcium-channel blocker use, diuretics use, 
angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers use, total 
cholesterol, HDL cholesterol, triglyceride, statin or other lipid-lowering agent, 
hemoglobin A1c, thiazolidinedione use, insulin use, urinary albumin-creatinine ratio, and 
estimated glomerular filtration rate. 
 
Figure 2: Adjusted hazard ratios and 95% CIs for heart failure according to a one 
standard deviation increment in the biomarker. 
Abbreviations: ECG, electrocardiogram; HR, hazard ratio; hs-CRP, high-sensitivity C-
reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IL-6, interleukin-6; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation. 
Model 1 was adjusted for age, sex, randomised blood pressure-lowering intervention, 
and randomised glucose control intervention. 
Model 2 was additionally adjusted for duration of diabetes mellitus, current smoking, 
history of myocardial infarction, history of hospitalization for heart failure, BMI, 
systolic blood pressure, heart rate, current or previous atrial fibrillation, pathological Q-
wave on ECG, left ventricular hypertrophy on ECG, aspirin or other antiplatelet agent 
use, β-blocker use, calcium-channel blocker use, diuretics use, angiotensin-converting 
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enzyme inhibitors or angiotensin II receptor blockers use, total cholesterol, HDL 
cholesterol, triglyceride, statin or other lipid-lowering agent, hemoglobin A1c, 
thiazolidinedione use, insulin use, urinary albumin-creatinine ratio, and estimated 
glomerular filtration rate. 
Model 3 was additionally adjusted for the other biomarkers. 
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